Found 17 results
Author Title [ Type(Desc)] Year
Filters: Author is Smith, C  [Clear All Filters]
Conference Paper
H. Ogutu, Wakasiaka, S., Malogo, R., Ndambuki, R., Nyange, J., Omosa, G., Anzala, O., Bwayo, J., Fast, P., Schmidt, C., Verlinde, C., Smith, C., Ndinya-Achola, J., and Jaoko, W., Challenges of Use and Compliance With Effective Contraceptives Among Female Participants in Preventive HIV Vaccine Trials: The Kenyan Experience, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
B. Peters, Jaoko, W., Anzala, O., Judges, L., G Manyonyi, O., Sharp, A., Gray, K., Fast, P., Schmidt, C., Gilmour, J., Smith, C., Dally, L., Loughran, K., Farah, B., Tarragona, T., Hayes, P., McMichael, A., Hanke, T., and Bwayo, J., Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
E. Vardas, Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., McIntyre, J., Gray, G., Bogoshi, M., Mayaphi, S., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., and Dally, L., Safety and Immunogenicity of MVA.HIVA by 3 Different Routes, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
W. Jaoko, Kayitenkore, K., G Manyonyi, O., Karita, E., Schmidt, C., Fast, P., Komaroff, W., Cooper, A., Boaz, M., Gilmour, J., Dally, L., Ho, M., Smith, C., and Graham, B., Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
Journal Article
C. Schmidt, Smith, C., Barin, B., Bakhtyari, A., Bart, P. A., Bekker, L. G., Chomba, E., Clumeck, N., Ho, D., Hoosen, A., Jaoko, W., Kaleebu, P., Karita, E., Keefer, M. C., Lunzen, J. V., McMichael, A., Mehendale, S., Peters, B., Ramanathan, V. D., Robinson, A., Rockstroh, J., Vardas, E., Vets, E., Weber, J., Graham, B. S., Than, S., Excler, J. L., Kochhar, S., Ho, M., Heald, A., and Fast, P. E., Background Morbidity in HIV Vaccine Trial Participants From Various Geographic Regions as Assessed by Unsolicited Adverse Events, Hum Vaccin Immunother, vol. 8, no. 5, pp. 630-638, 2012.
P. F. Wright, Mestecky, J., McElrath, M. J., Keefer, M. C., Gorse, G. J., Goepfert, P. A., Moldoveanu, Z., Schwartz, D., Spearman, P. W., R Habib, E., Spring, M. D., Zhu, Y., Smith, C., Flores, J., and Weinhold, K. J., Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing Either HIV-1 Genes or the Gene for Rabies Virus G Protein, J Infect Dis, vol. 189, no. 7, pp. 1221-1231, 2004.
B. Graham, McElrath, M., Keefer, M., Rybczyk, K., Berger, D., Weinhold, K., Ottinger, J., Ferarri, G., Montefiori, D., Stablein, D., Smith, C., Ginsberg, R., Eldridge, J., Duerr, A., Fast, P., and Haynes, B., Immunization With Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, But Causes Sterile Abscesses and Unacceptable Reactogenicity, PLoS One, vol. 5, no. 8, p. e11995, 2010.
S. Vasan, Hurley, A., Schlesinger, S. J., Hannaman, D., Gardiner, D. F., Dugin, D. P., Boente-Carrera, M., Clark, L., Dally, L., Smith, C., Schmidt, C., Park, H. H., Kopycinski, J. T., Gilmour, J., Fast, P., Bernard, R., and Ho, D. D., In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers, PLoS One, vol. 6, p. e19252, 2011.
N. Goonetilleke, Moore, S., Dally, L., Winstone, N., Cebere, I., Mahmoud, A., Pinheiro, S., Gillespie, G., Brown, D., Loach, V., Roberts, J., Guimar-Walker, A., Hayes, P., Loughran, K., Smith, C., DeBont, J., Verlinde, C., Vooijs, D., Schmidt, C., and McMichael, A. [..], Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA-and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing [..] Epitopes, J Virol, vol. 80, pp. 4717-4728, 2006.
A. Guimarães-Walker, Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., Barin, B., McMichael, A., Weber, J., Legg, K., Babiker, A., Hayes, P., Gotch, F., Smith, C., Dally, L., Dorrell, L., Cebere, I., Kay, R., Winstone, N., Moore, S., Goonetilleke, N., and Fast, P., Lessons from IAVI-006, a Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the PTHR.HIVA DNA and MVA.HIVA Vaccines in a Prime-Boost Strategy to Induce HIV-1 Specific T-Cell Responses in Healthy Volunteers, Vaccine, vol. 26, no. 51, pp. 6671-6677, 2008.
S. Vasan, Schlesinger, S., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D., and Gilmour, J., Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine, PLoS ONE, vol. 5, p. e8617, 2010.
I. Cebere, Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J. E., Darwin, S. C., Fast, P. E., Conlon, C., Rowland-Jones, S., McMichael, A. J., and Hanke, T., Phase I Clinical Trial Safety of DNA- and Modified Virus Ankara-Vectored Human Immunodeficiency Virus Type 1 (HIV-1) Vaccines Administered Alone and in a Prime-Boost Regime to healthy HIV-1 Uninfected Volunteers, Vaccine, vol. 24, pp. 417-425, 2006.
D. B. Kaufman, III, G. W. Burke, Bruce, D. S., Johnson, C. P., Gaber, A. O., Sutherland, D. E. R., Merion, R. M., Gruber, S. A., Schweitzer, E., Leone, J. P., Marsh, C. L., Alfrey, E., Concepcion, W., Stegall, M. D., Schulak, J. A., Gores, P. F., Benedetti, E., Smith, C., Henning, A. K., Kuehnel, F., and , A prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation, American Journal of Transplantation, vol. 3, pp. 855-64, 2003.
B. Rivoire, Groathouse, N., TerLouw, S., K Neupane, D., Ranjit, C., B Sapkota, R., Khadge, S., Kunwar, C., Macdonald, M., Hawksworth, R., Thapa, M., Hagge, D., Tibbals, M., Smith, C., Dube, T., She, D., Wolff, M., ,, Sizemore, C., and Brennan, P., Safety and Efficacy Assessment of Two New Leprosy Skin Test Antigens: Randomized Double Blind Clinical Study, PLOS Neglected Tropical Diseases, vol. 8, p. e2811, 2014.
F. Nakwagala, Birungi, J., Schmidt, C., Nanvubya, A., Konde, C., Hughes, P., Mugisha, E., Johnson, B., Muluubya, A., Nielsen, L., Gilmour, J., Gibiansky, L., Smith, C., Fast, P., and Kaleebu, P., Safety and immunogenicity of HIV-1 clade A vaccines in healthy, HIV uninfected adult Ugandan volunteers, 2004.
J. W, FN, N., O, A., G, O. Manyonyi, J, B., A, N., F, B., K, B., H, O., S, W., L, M., W, W., J, O., M, O., J, I., J, N. - A., C, K., ,, Smith, C., Barin, B., Dally, L., ,, and Kaleebu, P., Safety and Immunogenicity of Recombinant Low-Dosage HIV-1 A Vaccine Candidates Vectored by Plasmid pTHr DNA or Modified Vaccinia Virus Ankara (MVA) in Humans in East Africa, Vaccine, vol. 26, pp. 2788-2795, 2008.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E., Graham, B., Koup, R., Bailer, R., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C., Bizimana, J., Tarragona-Fiol, T., Bergin, P., Hayes, P., Ho, M., Loughran, K., and Komaroff, W., Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa, PLoS ONE, vol. 5, p. e12873, 2010.